UA127787U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

Diagnostic method for the development of atherosclerosis includes clinical examination, examination of low and high density lipoprotein cholesterol levels, arteriography, determination of MTHFR C677T gene polymorphism in serum, endothelin content, TGF- (1, PSA, IL-67, homocytosis, homocytosis). , endothelin levels> 10 ng / ml, TGF- (1 <14 ng / ml, PSA> 6 mg / l, IL-6> 10 ng / l, homocysteine> 20 μmol / l diagnose the development of atherosclerosis.

Description

A useful model belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of cholesterol levels of low and high density lipoproteins, arteriography of Ts|A.N. Okorokov

Diagnosis of diseases of internal organs. - Vol. 6 - pp. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that the method of diagnosing the development of atherosclerosis, which includes the study of low and high-density lipoprotein cholesterol levels, arteriography, according to a useful model, in the blood serum of the patient determines the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of endothelin, transforming growth factor beta 1 (TGF-VI), C-reactive protein (CRP), interleukin b (IL-b), homocysteine. At a homozygous carrier of 677-TT, levels of endothelin 210 ng/ml, TFR-B1 "14 ng/ml, SRP 26 mg/l, IL-b6 "10 ng/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

Application of the method. During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. The polymorphism of the MTNEK C677T gene is determined in the patient's blood serum. The content of endothelin, TFR-VI, SRP, IL-6, and homocysteine is determined by the immunoenzymatic method. At a homozygous carrier of 677-TT, levels of endothelin 210 ng/ml, TFR-VI1 "14 ng/ml, SRP "6b mg/l, IL-6 "10 ng/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

An example of using the method.

Patient K., 56 years old, was hospitalized with a diagnosis of rheumatoid arthritis. Inspected.

Low and high density lipoprotein cholesterol levels were studied. An arteriography of vessels was performed. No signs of atherosclerosis were found. A gene polymorphism was determined in blood serum

MTNEK S677T. The content of endothelin, TFR-VI, SRP, IL-b was determined by immunoenzymatic method.

From homocysteine. Homozygous carrier 677-1TT was established. Levels of endothelin - 16.5 ng/ml, TFR-D1 - 8.5 ng/ml, SRP - 14 mg/l, IL-6 - 20 ng/l, homocysteine - 29 μmol/l. The development of atherosclerosis was diagnosed. Arteriographic confirmation of the diagnosis was obtained only after 12 months.

Thus, the proposed method makes it possible to establish a diagnosis at the early stages of the development of the process.

Claims (1)

USEFUL MODEL FORMULA A method of diagnosing the development of atherosclerosis, which includes a clinical examination, a study of low and high-density lipoprotein cholesterol levels, arteriography, which is distinguished by that determine in blood serum the MTNEV C677T gene polymorphism, the content of endothelin, TFR-RI1, SRP, IL-6, homocysteine, with homozygous carrier 677-TT, endothelin levels 210 ng/ml, TFR-RI "14 ng/ml, SRP" b mg/l, IL-b6 »10 ng/l, homocysteine 220 μmol/l diagnose the development of atherosclerosis.